Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
11,2325 EMPA-REG OUTCOME was a randomized, double-blind, placebo-controlled trial involving 7,020 patients with T2D and established cardiovascular disease (CVD)
Obviously, this is an exaggeration, but it is kind of how it looks
Additional allegations include that the company failed to warn consumers and healthcare providers about the risks and used misleading advertising to downplay the risks while promoting its benefits
Injectors experience: Skilled professionals may charge more but ensure safety and results
Among patients who do fill their first script, an additional 36% discontinue after just one fill, a phenomenon known as "one & done" or non-persistent patient behavior
